Review
doi: 10.3390/ph14050435.Targeting Energy Expenditure-Drugs for Obesity Treatment
Affiliations
- PMID:34066399
- PMCID: PMC8148206
- DOI: 10.3390/ph14050435
Item in Clipboard
Review
Targeting Energy Expenditure-Drugs for Obesity Treatment
Carlos M Jimenez-Munoz et al. Pharmaceuticals (Basel)..
Display options
Format
Display options
Format
Abstract
Obesity and overweight are associated with lethal diseases. In this context, obese and overweight individuals infected by COVID-19 are at greater risk of dying. Obesity is treated by three main pharmaceutical approaches, namely suppressing appetite, reducing energy intake by impairing absorption, and increasing energy expenditure. Most compounds used for the latter were first envisaged for other medical uses. However, several candidates are now being developed explicitly for targeting obesity by increasing energy expenditure. This review analyzes the compounds that show anti-obesity activity exerted through the energy expenditure pathway. They are classified on the basis of their development status: FDA-approved, Withdrawn, Clinical Trials, and Under Development. The chemical nature, target, mechanisms of action, and description of the current stage of development are described for each one.
Keywords: FDA-approved; clinical trials; energy expenditure; energy metabolism; obesity; thermogenesis; treatments under development; withdrawn treatments.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Excess intake of calories causes overweight and obesity. There are three main pharmacological strategies to achieve a caloric deficit. Two of them aim to prevent the storage of excess calories, first by acting on the central nervous system to cause an anorexic effect and regulate appetite, and second by inducing early excretion and thus preventing ingested food from becoming a useful source of calories. The third strategy, and the topic of this review, is the use of drugs that increase energy expenditure by causing the body to use calories already stored in the form of fat.
Drugs, their targets, and their metabolic outcomes focusing on energy expenditure effect.
Chemical structures of drugs that increase energy expenditure that are approved by the FDA and withdrawn from the market.
Drugs that increase energy expenditure in clinical trials.
Drugs under development that increase energy expenditure.
Similar articles
- Pharmacological approaches for the treatment of obesity.Fernández-López JA, Remesar X, Foz M, Alemany M.Fernández-López JA, et al.Drugs. 2002;62(6):915-44. doi: 10.2165/00003495-200262060-00005.Drugs. 2002.PMID:11929339Review.
- The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.Sjödin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, Meier D, Astrup A.Sjödin A, et al.Int J Obes (Lond). 2010 Nov;34(11):1634-43. doi: 10.1038/ijo.2010.87. Epub 2010 May 18.Int J Obes (Lond). 2010.PMID:20479765Clinical Trial.
- [Pharmacological therapy of obesity].Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.Pagotto U, et al.G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S.G Ital Cardiol (Rome). 2008.PMID:18773755Italian.
- Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.Bergmann NC, Lund A, Gasbjerg LS, Meessen ECE, Andersen MM, Bergmann S, Hartmann B, Holst JJ, Jessen L, Christensen MB, Vilsbøll T, Knop FK.Bergmann NC, et al.Diabetologia. 2019 Apr;62(4):665-675. doi: 10.1007/s00125-018-4810-0. Epub 2019 Jan 25.Diabetologia. 2019.PMID:30683945Clinical Trial.
- Thermogenic responses induced by nutrients in man: their importance in energy balance regulation.Jequier E.Jequier E.Experientia Suppl. 1983;44:26-44. doi: 10.1007/978-3-0348-6540-1_3.Experientia Suppl. 1983.PMID:6357848Review.
Cited by
- Hederagenin fromHedera helix Promotes Fat Browning in 3T3-L1 Adipocytes.Choi SM, Lee HS, Lim SH, Choi G, Choi CI.Choi SM, et al.Plants (Basel). 2024 Oct 4;13(19):2789. doi: 10.3390/plants13192789.Plants (Basel). 2024.PMID:39409659Free PMC article.
- Mitophagy Mediates the Beige to White Transition of Human Primary Subcutaneous Adipocytes Ex Vivo.Vámos A, Shaw A, Varga K, Csomós I, Mocsár G, Balajthy Z, Lányi C, Bacso Z, Szatmári-Tóth M, Kristóf E.Vámos A, et al.Pharmaceuticals (Basel). 2022 Mar 17;15(3):363. doi: 10.3390/ph15030363.Pharmaceuticals (Basel). 2022.PMID:35337160Free PMC article.
- Antiobesity effect ofKaempferia parviflora accompanied by inhibition of lipogenesis and stimulation of lipolysis.Park SH, Park J, Lee M, Kim J, Eun S, Jun W, Kim OK, Lee J.Park SH, et al.Food Nutr Res. 2023 Jul 3;67. doi: 10.29219/fnr.v67.9374. eCollection 2023.Food Nutr Res. 2023.PMID:37441513Free PMC article.
- Melanocortin-4 receptor complexity in energy homeostasis,obesity and drug development strategies.Fatima MT, Ahmed I, Fakhro KA, Akil ASA.Fatima MT, et al.Diabetes Obes Metab. 2022 Apr;24(4):583-598. doi: 10.1111/dom.14618. Epub 2022 Jan 11.Diabetes Obes Metab. 2022.PMID:34882941Free PMC article.Review.
- BMP7 Increases UCP1-Dependent and Independent Thermogenesis with a Unique Gene Expression Program in Human Neck Area Derived Adipocytes.Shaw A, Tóth BB, Arianti R, Csomós I, Póliska S, Vámos A, Bacso Z, Győry F, Fésüs L, Kristóf E.Shaw A, et al.Pharmaceuticals (Basel). 2021 Oct 25;14(11):1078. doi: 10.3390/ph14111078.Pharmaceuticals (Basel). 2021.PMID:34832860Free PMC article.
References
- World Health Organisation Obesity and Overweight. [(accessed on 1 November 2019)]; Available online:https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
Publication types
Related information
LinkOut - more resources
Full Text Sources